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Abstract: There is a geographic inequality in the incidence of colorectal cancer, lowest in developing
countries, and greatest in developed countries. This disparity suggests an environmental contribution
to cancer resistance in endemic populations. Enterotoxigenic bacteria associated with diarrheal
disease are prevalent in developing countries, including enterotoxigenic E. coli (ETEC) producing
heat-stable enterotoxins (STs). STs are peptides that are structurally homologous to paracrine
hormones that regulate the intestinal guanylyl cyclase C (GUCY2C) receptor. Beyond secretion,
GUCY2C is a tumor suppressor universally silenced by loss of expression of its paracrine hormone
during carcinogenesis. Thus, the geographic imbalance in colorectal cancer, in part, may reflect
chronic exposure to ST-producing organisms that restore GUCY2C signaling silenced by hormone
loss during transformation. Here, mice colonized for 18 weeks with control E. coli or those engineered
to secrete ST exhibited normal growth, with comparable weight gain and normal stool water content,
without evidence of secretory diarrhea. Enterotoxin-producing, but not control, E. coli, generated
ST that activated colonic GUCY2C signaling, cyclic guanosine monophosphate (cGMP) production,
and cGMP-dependent protein phosphorylation in colonized mice. Moreover, mice colonized with
ST-producing E. coli exhibited a 50% reduction in carcinogen-induced colorectal tumor burden.
Thus, chronic colonization with ETEC producing ST could contribute to endemic cancer resistance in
developing countries, reinforcing a novel paradigm of colorectal cancer chemoprevention with oral
GUCY2C-targeted agents.
Keywords: enterotoxigenic E. coli; heat-stable enterotoxins; azoxymethane; colorectal cancer;
GUCY2C-cGMP axis; chemoprevention
1. Introduction
Enterotoxigenic E. coli (ETEC) remain a major public health issue, causing almost 1 billion illnesses
and half a million deaths worldwide each year, with deaths mostly occurring in developing countries
in children less than 5 years old [1–3]. ETEC is a heterogeneous classification of bacteria, comprising
molecular subtypes of E. coli identified by their toxins that produce secretion. These include heat-labile
enterotoxins (LT) which are structurally homologous to cholera toxin and induce cyclic adenosine
monophosphate (cAMP) accumulation, and heat-stable enterotoxins (STa and STb) which induce
cGMP accumulation [1]. Of these, STa (ST) is the predominant form associated with human disease,
comprising 18 amino acids containing three intrachain disulfide bonds that provide the structural
stability underlying its resistance to heat-induced denaturation [1].
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ST is structurally homologous to the paracrine hormones guanylin (GUCA2A) and uroguanylin
(GUCA2B) which activate the intestinal guanylyl cyclase C (GUCY2C) receptor [4]. However, compared
to these endogenous hormones, which contain only two disulfide bonds, ST is resistant to proteolysis,
isomerically stable, pH-insensitive, and has a higher receptor affinity resulting in excess GUCY2C
activation in the small intestine leading to diarrhea. Binding of ST to the extracellular receptor
domain of GUCY2C activates the cytoplasmic catalytic domain that converts GTP to cyclic GMP
(cGMP) [4]. In turn, cyclic nucleotide accumulation activates cGMP-dependent protein kinase (PKG)
which phosphorylates and opens the cystic fibrosis transmembrane conductance receptor (CFTR),
a channel permeable to chloride and bicarbonate ions. Chloride ions flow down their electrochemical
gradient into the intestinal lumen, leading to electrogenic sodium flux and water secretion resulting
in secretory diarrhea. This pathophysiological mechanism is the basis for the development of the ST
analog linaclotide (Linzess™) approved by the FDA to treat patients with chronic constipation and
constipation-type irritable bowel syndrome [5].
Beyond intestinal secretion, the guanylin-GUCY2C paracrine axis comprises a tumor suppressing
circuit whose dysregulation universally characterizes colorectal carcinogenesis across species [6,7].
Indeed, guanylin is one of the most commonly lost gene products in colorectal tumorigenesis
and its loss is one of the earliest events in malignant transformation in mice and humans [6,8,9].
Loss of guanylin silenced GUCY2C producing intestinal epithelial dysfunction disrupting homeostatic
mechanisms organizing the crypt-villus axis including proliferation, DNA damage sensing and repair,
and metabolic programming, which contribute to tumorigenesis [10–14]. Further, silencing GUCY2C
amplified intestinal tumorigenesis induced by carcinogens or genetic mutations in mice [10–12].
Moreover, GUCY2C ligand replacement opposed mutational or carcinogen-induced intestinal
carcinogenesis in mice [9,12]. In that context, GUCY2C ligand replacement is emerging as a novel
paradigm for colorectal cancer chemoprevention [15,16].
Colorectal cancer is the third leading cause of cancer and the fourth leading cause of
cancer-related mortality in the world, with a geographic distribution primarily affecting patients
in developed, compared to developing, countries [17–21]. The epidemiology of this disease remains
incompletely understood, and its complexity reflects contributions of diet, lifestyle, comorbidities,
environmental exposures, access to healthcare, and socioeconomic factors [17–21]. Interestingly,
there is an unexplained inverse relationship between the incidence of colorectal cancer and ETEC
infections [9,14]. Indeed, the age-adjusted incidence of colorectal cancer is lowest in under-developed
countries where ETEC infections are highest [14,18,19,21]. The role of GUCY2C as a tumor suppressor
and the loss of guanylin expression in tumor pathophysiology could represent one contributing factor
to this inverse epidemiological association between colorectal cancer and ETEC infections, reflecting
longitudinal exposure to ST-producing bacteria in developing countries. Here, we reveal for the first
time that chronic colonization of mice with E. coli producing ST opposes the development of colorectal
tumors induced by the carcinogen azoxymethane (AOM). These studies support the hypothesis
of an environmental contribution to the disparity in colorectal cancer incidence in developed and
developing countries, mediated by chronic exposure to ST-producing bacteria [14]. Moreover, it
underscores the emerging paradigm of oral GUCY2C ligand replacement as a novel approach to
the chemoprevention of colorectal cancer [9,11,15].
2. Methods and Materials
Recombinant bacteria. An ST-secreting construct containing the ST pro-peptide sequence [22]
was generated using the pET101/D-TOPO ampicillin-resistant plasmid vector (cat# K10101;
Thermo Fisher Scientific, Philadelphia, PA, USA). BL21, a chemically competent E. coli suitable for
protein expression (New England Biolabs, Ipswich, MA, USA), was transformed using the recombinant
ST-containing construct to generate ST-secreting E. coli [BL21(ST+)]. BL21 E. coli transformed with
empty plasmid vector (no ST secretion) served as a negative control [BL21(ST−)].
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Mouse and bacterial colonization. SWR/J mice (Jackson Laboratory, Bar Harbor, ME, USA),
susceptible to AOM-induced colon carcinogenesis, received drinking water ad libitum containing
ampicillin (1 g/L) for 1 week at 3 weeks of age, followed by oral gavage with bacteria in 200 µL PBS
(OD = 1.0) at 4 weeks of age. Mice received water ad libitum containing ampicillin for the duration
of the experiments to maintain intestinal bacterial colonization. Bacteria were isolated from mouse
stool weekly starting at week 5 to week 18 [23] and stool weight was used to normalize the colony
forming units for both BL21(ST−) and BL21(ST+). While each cohort initiated with 25 mice, 23 mice in
the BL21(ST−), and 22 mice in the BL21(ST+), survived to the analytical endpoint (18 weeks of age).
Enterotoxin quantification by EIA. BL21(ST−) and BL21(ST+) isolated from mouse stool were
maintained in Luria-Bertani (LB) broth and supernatants were collected for quantification of ST
secretion. ST was quantified using the COLIST enzyme immunoassay (EIA) (Denka Seiken, San Jose,
CA, USA).
Azoxymethane (AOM) tumorigenesis. Animal protocols were approved by the Thomas Jefferson
University Institutional Animal Care and Use Committee (IACUC). Mice (6 weeks old) received
intraperitoneal injections (12 mg/kg body weight) of AOM weekly for 6 weeks, and 12 weeks after the
first injection were sacrificed and intestines examined for tumors.
Immunoblot analysis. Protein was extracted from tissues, lysed in Laemmli buffer supplemented
with protease and phosphatase inhibitors (Roche; Sigma-Aldrich, Allentown, PA, USA). Lysates were
analyzed by SDS-PAGE (NUPAGE 4–12% bis tris gel; Novex Life Technologies; Thermo Fischer
Scientific, Philadelphia, PA, USA) and electrophoretically transferred to a nitrocellulose membrane
(Novex Life Technologies). Membranes were blocked with 5% BSA in PBST (1X PBS and 1%
Tween 20) and probed overnight with antibodies to p-ser157-VASP (#3111, 1:1000; Cell Signaling
Technology, Danvers, MA, USA) and GAPDH (#2118, 1:5000; Cell Signaling Technology) followed
by incubation with goat anti-mouse horseradish peroxidase (HRP)-conjugated and goat anti-rabbit
HRP-conjugated secondary antibodies (1:50,000, Jackson ImmunoResearch, West Grove, PA, USA).
Blots were developed in SuperSignal West Dura enhanced chemiluminescence substrate (Thermo
Fischer Scientific). Relative intensity was quantified by densitometry using ImageJ and normalized to
GAPDH. Results reflect the average relative intensity ± SD for ≥3 independent experiments.
ST and control peptides. ST1-18 was purchased from Bachem Co. (customer order;
purity > 99.0%). ST was prepared by solid phase synthesis and purified by reverse phase HPLC,
their structure confirmed by mass spectrometry by Bachem Co. (customer order; purity > 99.0%).
ST activity was quantified by guanylate cyclase activation and secretion in the suckling mouse assay
as described [24,25].
Pathophysiological parameters. Cyclic GMP was quantified by radioimmunoassay [10,12–14,26].
Stool water content was estimated by quantifying differences in stool weight before and after oven
desiccation. Tumors were enumerated and their size quantified under a dissecting microscope in
a blinded fashion. Tumor burden per animal was quantified by calculating the sum of the (diameter2)
of individual tumors in each mouse [10,12]. All tumors from AOM-treated mice were histologically
confirmed by a pathologist (PL) blinded to information for each case.
Statistical analyses. All data were analyzed using GraphPad Prism v6. Measurements were
analyzed by ANOVA or Students t-test, unless otherwise indicated. Number of tumors per animal was
analyzed by Poisson regression. Tumor burden and tumor size (mm2) in the continuous scale were
analyzed by linear mixed models, with random effect of animal to control for multiple measures
per animal. Tumor number, size and burden per animal were categorized and analyzed using
Mantel-Hanzel (MH) exact chi-square tests for trend. p < 0.05 was considered statistically significant.
Error bars depict 95% CI unless otherwise specified.
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3. Results
3.1. Chronic BL21 Colonization and ST Production
BL21(ST+) secreted immunoreactive heat-stable enterotoxin compared to BL21(ST−) (Figure 1A,B).
These bacteria continuously colonized mice for 18 weeks, evidenced by their recovery in
stool (Figure 1C). Colonization was limited to the colorectum, but not the small intestine (Figure 2A,B).
In that context, BL21(ST+) secreted ST in colonized mice, activating GUCY2C and increasing cGMP
accumulation (Figure 2B) and cGMP-dependent protein phosphorylation of VASP (Figure 2C),
a canonical downstream target of cGMP signaling [27] (Figure 2C,D) in epithelial cells of the colon,
but not the jejunum and ileum (data not shown). The effects of ST secreted by colonizing BL21(ST+)
precisely mimicked those of synthetic biologically active ST (Figure 3A), which also activated GUCY2C
and increased cGMP production (Figure 3B) and phosphorylation of VASP (Figure 3C) in intestinal
epithelia. Mice colonized with BL21(ST+) and chronically exposed to ST exhibited normal growth
characteristics, with weight gains that were comparable to mice colonized with BL21(ST−) (Figure 4A).
Moreover, colorectal colonization with BL21(ST+) and chronic exposure to ST did not induce diarrhea,
and water content of stool was comparable to that produced by mice chronically colonized with
BL21(ST−) (Figure 4B).
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Mice chronically colonized with BL21(ST+) [ST(+)] or BL21(ST−) [ST(−)]. (A) experienced growth,
quantified by weight gain, and (B) exhibited stool water content, that was comparable to control mice
[no recombinant bacteria (CTRL, Control)]. n = 5 mice per group; assays were performed in triplicate;
error bars represent 95% CI. F, female; M, male.
3.2. BL21(ST+) Colonization Opposes Carcinogen-Induced Colorectal Tumorigenesis
AO is a pro-carcinogen that is pro oted in the liver to a DNA alkylating agent and utagen,
which induces intestinal tumors specifically in the colorectum [10,11]. AOM-induced tumors in
mice chronically colonized with BL21(ST−) or BL21(ST+) (Figure 5A,B). However, colonization with
BL21(ST+) inhibited tu or initiation, reflected by a lo er nu ber of tu ors co pared to ice
colonized ith BL21(ST−) (Figure 5C; p < 0.05). Also, colonization ith BL21(ST+) inhibited tu or
progression, reflected by significantly (p < 0.001) s aller tu ors co pared to ice colonized ith
BL21(ST−) (Figure 5D). Indeed, these effects on tumor initiation and progression resulted in a reduction
in overall tumor burden of more than 50% in mice colonized with BL21(ST+) compared to mice
colonized with BL21(ST−) (Figure 5E; p < 0.001).
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4. Discussion
Diarrheal disease remains one of the leading causes of morbidity and mortality worldwide,
responsible for 2.3 billion illnesses and 4% of all deaths annually [1–3]. ST−producing ETEC are
a principal cause, with nearly a billion episodes, resulting in ~500,000 deaths, annually [28–30].
Importantly, the burden of diarrheal disease is concentrated in geographic regions that are
under-developed, with negligible rates in industrialized countries [1,3,28–30]. While the clinical
impact is greatest in particularly vulnerable populations, including children and the elderly, carriage
rates of ST-producing ETEC in otherwise healthy individuals are substantial in endemic regions,
reflecting chronic colonization in the absence of disease [1,3,28–30].
Colorectal cancer is the third most common cancer and the fourth most common cause
of cancer death worldwide, accounting for >9% of cancer incidence and a million new cases
annually [17,19,20]. Colorectal cancer is mainly a disease of industrialized countries [31] and developed
countries account for >63% of all cases [20,32]. Indeed, incidence varies up to 10-fold between
developed and under-developed countries, with >40 per 100,000 people in Westernized countries
compared to <5 per 100,000 in under-developed geographic regions [17,20,33]. While there is a striking
inverse epidemiological relationship between diarrheal diseases related to ST-producing ETEC and
colorectal cancer, mechanisms contributing to this inverted linkage remain undefined [9,14].
ST-producing ETEC induce diarrhea by binding to GUCY2C, the intestinal isoform of
membrane-bound guanylyl cyclase [4,24,34]. STs are an example of convergent evolution in
which bacteria evolved a peptide that is a molecular mimic of the paracrine hormone guanylin,
the endogenous ligand in the colorectum for GUCY2C [4]. Binding of endogenous (guanylin) or
exogenous (STs) ligands to GUCY2C increases intracellular cyclic GMP (cGMP) [4,24,34–37]. In turn,
GUCY2C-cGMP induces phosphorylation of the CFTR resulting in epithelial secretion, one mechanism
by which bacteria induce diarrhea [4,38–40].
Beyond secretion, GUCY2C regulates intestinal epithelial homeostasis, including key component
processes canonically disrupted in cancer [4,10–12,14,15]. Thus, guanylin loss expands the proliferating
crypt compartment in colon, and silencing GUCY2C produces crypt hyperplasia by accelerating
the enterocyte cell cycle [10–14,26,41]. Also, intestinal epithelia exhibit a metabolic gradient along
the crypt-surface axis, where proliferating crypt cells generate ATP through glycolysis, while
differentiated surface cells depend on oxidative phosphorylation [12]. Silencing GUCY2C imposes
a glycolytic metabolic phenotype along the crypt-surface axis, with reduced mitochondrial content
and function, increased glycolytic enzyme content, decreased oxygen consumption, and accumulation
of lactate, recapitulating the Warburg metabolic phenotype in tumors [12]. Further, silencing GUCY2C
increases DNA oxidation, double strand DNA breaks, mutations in tumor suppressor genes, and
chromosomal instability [10,12].
In the context of this key role in epithelial homeostasis, guanylin is universally lost early
in tumorigenesis, silencing GUCY2C, and this early hormone loss is a disease mechanism
conserved in mice and humans [7–9,42,43]. Silencing GUCY2C signaling increases transcriptional
programs driving tumorigenesis [10–12]. Indeed, eliminating GUCY2C expression amplified [10],
while oral GUCY2C ligand reduced [9], tumors in mouse models mimicking human colorectal
carcinogenesis. Further, transgenic guanylin expression that cannot be suppressed eliminated tumors
in carcinogen-induced mouse models of colorectal cancer [11]. Taken together, these observations
suggest a pathophysiological hypothesis that guanylin loss silencing GUCY2C signaling is an essential
step in colorectal tumorigenesis [15]. Moreover, it suggests the correlative therapeutic hypothesis
that oral GUCY2C ligand replacement may be a tractable approach to prevent colorectal cancer in
patients [16].
This role for guanylin loss silencing GUCY2C in intestinal tumorigenesis suggests that the inverse
epidemiological relationship between diarrheal disease and colorectal cancer could, in part, reflect
chronic colonization in endemic areas with ST-producing ETEC [9,14]. In this model, chronic
colonization with ETEC supplies exogenous ST that, in turn, reconstitutes GUCY2C signaling silenced
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by loss of the endogenous paracrine hormone guanylin, a universal step in tumorigenesis. Here, we
demonstrate that mice continuously colonized with E. coli producing ST in the colorectum exhibit
normal growth, without evidence of diarrheal disease, representing a model that recapitulates
otherwise healthy patients in endemic areas chronically colonized with ETEC. Indeed, while these mice
remain asymptomatic, ST is secreted into their intestinal lumens, binding to GUCY2C and stimulating
cGMP production and signaling. Importantly, chronic colonization by ST-producing E. coli reduces
the ability of the carcinogen AOM to initiate tumors (number), and drive their progression (size),
diminishing tumor burden by >50%, compared to mice colonized by control E. coli.
Taken together, these observations demonstrate that chronic colonization with ST-producing E. coli
reduces intestinal tumorigenesis induced by the carcinogen AOM. They support the hypothesis that
the inverse epidemiological relationship between colorectal cancer and infectious diarrheal disease,
at least in part, reflects a contribution of chronic colonization by ETEC that produce ST. In that
context, our working hypothesis, yet to be directly tested, suggests that bacterially produced ST
replaces guanylin lost during tumorigenesis, restoring GUYC2C signaling, which opposes tumor
transformation [9,14,15]. Further, they support the pathophysiological hypothesis that colorectal cancer
initiates as a disease of paracrine hormone insufficiency [15]. Moreover, they support the therapeutic
hypothesis that colorectal cancer might be prevented by oral GUCY2C ligand replacement [9,11,15].
The immediate tractability of this therapeutic approach is underscored by the recent approval of
linaclotide (Linzess™) and plecanatide (Trulance™), oral GUCY2C ligands approved for the treatment
of chronic constipation syndromes [16,44].
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